Dr Christophe Lacroix
Director of Translational Center of Tissue Chip Technologies
(Massachusetts Institute of Technology)
Paper presenting: Translational applications of microphysiological systems
Murat Cirit, PhD, is a Research Scientist at MIT & director of the Translational Systems Pharmacology Team. Murat completed his PhD at NCSU focusing on systems biology of growth factor-mediated signal transduction pathways. After completion of his PhD, he worked in the pharmaceutical industry focusing on preclinical drug discovery for oncology. He brings an interdisciplinary and systematic approach through his extensive experimental knowledge and computational modeling with an understanding of biological, physiological, and physical processes. His main research experience is systems pharmacology, systems biology, applied tissue engineering, cell biology and signal transduction networks. His current focus as the scientific lead is integrating various scientific fields to build interacting MPSs by interfacing platform engineering & tissue engineering for pharmacology studies.
Head of Toxicology
Paper presenting: Combined in silico and 3D in vitro approaches for the accurate prediction of human drug induced liver injury
Paul Walker is the Head of Toxicology at Cyprotex where he is responsible for the development of new assays and management of client work performed within the Toxicology Group.
Paul obtained his Ph.D. from King’s College London in Molecular Toxicology being awarded the Tadion-Rideal prize for molecular sciences (2004). Paul further developed his understanding of molecular biology and toxicology during his post-doctoral years at the University of Manchester with a keen interest in the application of high content screening within this field.
Paul joined Cyprotex in 2010 with his research interests focused on the role of drug metabolism in drug toxicity and in vitro assays to predict toxicity in early drug discovery.
His team are focused on:
1. Developing and evaluating novel cellular systems to improve the prediction of toxicity.
2. Evaluate current industry utilised mechanistic endpoint assays in predicting toxicity.
3. The importance of drug metabolism and appropriate cellular models in our mechanistic understanding of toxicity.
4. Integrating in vivo exposure in interpretation of in vitro data, and 5. Modelling approaches combining ADME, PK and in vitro Tox assays to predict toxicity.